Items Tagged ‘Progressive Relapsed Hodgkin’s Lymphoma’

June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


October 6th, 2015

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma

By

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the journal Blood. Hodgkin’s lymphoma is a type of cancer of the immune system. Standard therapy for Hodgkin’s often includes […]

View full entry

Tags: adcetris, brentuximab vedotin, CD30., Hodgkin's Lymphoma, MMAE, News, Progressive Relapsed Hodgkin's Lymphoma


May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

By

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]

View full entry

Tags: adcetris, Autologous Stem Cell Transplant, brentuximab vedotin, HL, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma, refractory, relapsed


December 23rd, 2014

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th Annual Meeting, PD-1 blockade has demonstrated efficacy in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, hodgkin's disease, Hodgkin's Lymphoma, keytruda, Lymphoma, News, pembrolizumab, Progressive Relapsed Hodgkin's Lymphoma


December 18th, 2014

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of Medicine, PD-1 blockade has demonstrated effectiveness in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is a […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, HL, Hodgkin's Lymphoma, Lymphoma, News, nivolumab, PD-1, Progressive Relapsed Hodgkin's Lymphoma


January 16th, 2014

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma

By

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented at the 2013 International Symposium on Hodgkin Lymphoma in Cologne, Germany. Hodgkin’s lymphoma is a cancer of the lymph system. It […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


January 14th, 2014

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma

By

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th International Symposium on Hodgkin Lymphoma held in Cologne, Germany in 2014. Hodgkin’s lymphoma is a cancer of […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


August 26th, 2011

Adcetris Approved for Two Types of Lymphoma

By

The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Progressive Relapsed Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma


May 23rd, 2011

Many Patients with “Chemo Brain” Recover within Five Years

By

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist for more than five years after treatment. These findings were recently reported in the Journal of Clinical Oncology. Chemo brain refers […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Adult Acute Lymphoblastic Leukemia, Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, Allogeneic Stem Cell Transplant, Childhood Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Early Stage Hodgkin's Lymphoma


January 12th, 2011

Targeted Therapy Promising for Relapsed Hodgkin Lymphoma

By

In a Phase II clinical trial, three-quarters of patients with relapsed or refractory Hodgkin lymphoma responded to treatment with the investigational drug brentuximab vedotin. These results were presented at the 2010 annual meeting of the American Society of Hematology. Hodgkin lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes […]

View full entry

Tags: Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


February 5th, 2009

Hodgkin's Survivors: Increased Fatigue, Cardiac, and Thyroid Complications

By

According to an article published in the Annals of Oncology, survivors of Hodgkin’s lymphoma have a significantly increased rate of cardiac and thyroid complications than their siblings. In addition, survivors tend to have more fatigue than their siblings; however, this may in part be associated with cardiac issues. Researchers from the Brigham and Women’s Hospital […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, Progressive Relapsed Hodgkin's Lymphoma